Moderna Inc said on Monday it expected to record sales of about US$18.5 billion in 2022 from contracts for its COVID-19 vaccine, and about US$3.5 billion from potential additional purchases including booster candidates updated for variants.
The company in November said its sales could be in the range of US$17 billion to US$22 billion in 2022.
Moderna said it was in active discussions for additional COVID-19 vaccine contracts this year.
The company also said it was developing a booster vaccine candidate, called mRNA-1273.529, that targets the fast-spreading Omicron variant and expects it to advance into clinical trials in early 2022.
Booster doses of the company’s current COVID-19 vaccine, mRNA-1273, increased neutralizing antibody levels against Omicron at both 50 microgram and 100 microgram dose levels, the drugmaker said.
